Clinical trials: Waldenstrom Macroglobulinaemia
Waldenstrom Macroglobulinemia
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally.
- Trial name
- RAINBOW (NCT04061512)
- Testing
- Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
- Where
- 25 sites in United Kingdom
- Volunteers
- 148 people
- Sponsor
- University College, London
Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
Efficacy and Safety of ibrutinib in patients with chronic lymphocytic leukemia and other indolent B-cell lymphomas who are chronic hepatitis B virus carriers or occult hepatitis B virus carriers
- Conditions
- Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas, Chronic Hepatitis B, Lymphoma, Small Lymphocytic
- Trial name
- NCT02991638
- Testing
- Ibrutinib
- Where
- Hong Kong
- Volunteers
- 62 people
- Sponsor
- The University of Hong Kong
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has…
- Conditions
- Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
- Trial name
- NCT04578600
- Testing
- Lenalidomide, Obinutuzumab, Oral Azacitidine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Joseph Tuscano